NEW YORK — Immune profiling firm Immunai said on Thursday that it has acquired single-cell genomics software company Dropprint Genomics for an undisclosed amount.
New York City-based Immunai, which has offices in San Francisco and Tel Aviv, said the acquisition is providing it with technologies San Francisco-based Dropprint has developed for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples.
Additionally, Dropprint, a Y Combinator-backed startup, has built a database of immune cell profiles from autoimmune and cancer patients that Immunai will incorporate into its Annotated Multi-omic Immune Cell Atlas (AMICA).
Dropprint's employees, including cofounders Meena Subramaniam and Rachel Gate, are joining Immunai's machine learning and computation biology team.
The acquisition comes a month after Immunai raised $60 million in a Series A financing round. The company said it has raised $80 million in funding to date.
For a more in-depth look at Immunais acquisition of Dropprint, click here.